



2nd February, 2024

<p>To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p>Ref.: Scrip Code No. : 540701 (Equity) : 974556 (Debt)</p>	<p>To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p>Ref. : (i) Symbol – DCAL (ii) Series – EQ</p>
--	--

SUB.: DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS, 2015: COMPANY’S BAVLA SITE RECEIVED CERTIFICATE OF GMP COMPLIANCE FROM EDQM AND AIFA AUTHORITIES

Dear Sir,

We are pleased to inform that in respect of the successful inspection of the Bavla site conducted by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and Italian Medicines Agency (AIFA) Authorities in September 2023, the Company in addition to the “Attestation of Inspection” certificate, also received today the “Certificate of GMP (Good Manufacturing Practice) Compliance” from these authorities.

Thus, now the Company’s Bavla site is fully in compliance with the EU GMP guidelines.

Kindly take this on your record.

Thanking You,

Yours faithfully,
For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary